Equities research analysts expect Genmab A/S (NASDAQ:GMAB) to announce sales of $283.69 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Genmab A/S’s earnings, with estimates ranging from $263.63 million to $295.65 million. Genmab A/S posted sales of $438.89 million during the same quarter last year, which indicates a negative year-over-year growth rate of 35.4%. The company is expected to announce its next earnings report on Wednesday, February 17th.

According to Zacks, analysts expect that Genmab A/S will report full-year sales of $1.53 billion for the current financial year, with estimates ranging from $1.47 billion to $1.61 billion. For the next financial year, analysts anticipate that the company will report sales of $1.20 billion, with estimates ranging from $1.13 billion to $1.33 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Genmab A/S.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 4th. The company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.03. The firm had revenue of $273.43 million for the quarter, compared to the consensus estimate of $232.86 million. Genmab A/S had a net margin of 50.99% and a return on equity of 34.40%.

Several research analysts have issued reports on GMAB shares. Zacks Investment Research downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Thursday, January 7th. Morgan Stanley lifted their target price on shares of Genmab A/S from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Wednesday, December 16th. TheStreet downgraded shares of Genmab A/S from a “b” rating to a “c+” rating in a report on Tuesday, December 1st. BidaskClub downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Thursday, December 31st. Finally, SVB Leerink lowered their target price on shares of Genmab A/S from $36.00 to $34.00 and set a “market perform” rating on the stock in a report on Wednesday, December 9th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. Genmab A/S currently has a consensus rating of “Hold” and a consensus price target of $41.00.

Genmab A/S stock traded up $1.58 during midday trading on Friday, hitting $42.71. 21,722 shares of the company’s stock were exchanged, compared to its average volume of 415,686. Genmab A/S has a 12-month low of $16.24 and a 12-month high of $42.50. The stock has a market cap of $27.99 billion, a price-to-earnings ratio of 33.11, a price-to-earnings-growth ratio of 1.35 and a beta of 0.93. The firm’s 50 day simple moving average is $39.35 and its 200 day simple moving average is $36.92.

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Morgan Stanley raised its position in Genmab A/S by 24.0% during the first quarter. Morgan Stanley now owns 221,368 shares of the company’s stock worth $4,691,000 after acquiring an additional 42,804 shares during the last quarter. Bank of New York Mellon Corp raised its position in Genmab A/S by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 90,735 shares of the company’s stock worth $3,076,000 after acquiring an additional 6,079 shares during the last quarter. FMR LLC raised its position in Genmab A/S by 99.5% during the second quarter. FMR LLC now owns 17,220 shares of the company’s stock worth $584,000 after acquiring an additional 8,589 shares during the last quarter. Advisor Group Holdings Inc. raised its position in Genmab A/S by 48.2% during the second quarter. Advisor Group Holdings Inc. now owns 17,783 shares of the company’s stock worth $603,000 after acquiring an additional 5,782 shares during the last quarter. Finally, Glenmede Trust Co. NA raised its position in Genmab A/S by 70.5% during the second quarter. Glenmede Trust Co. NA now owns 1,790 shares of the company’s stock worth $60,000 after acquiring an additional 740 shares during the last quarter. Hedge funds and other institutional investors own 5.08% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Read More: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.